SAN FRANCISCO– (BUSINESS WIRE) – Florica Therapeutics, Inc. has received a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $ 255,678 to work on the Hypothalamus Stem Cell Exosomes for Treatment of COVID-19 project.
This Phase I grant will develop drugs capable of modulating the immune response to prevent escalation of COVID-19 to acute respiratory distress syndrome (ARDS). The hypothalamus is critical for the secretion of cortisol and other immunomodulators that dampen the immune response following immune activation. We will check whether exosome-based therapies have been produced from Stem cells from the hypothalamus can reduce the cytokine storm that is the leading cause of death in COVID-19 patients.
“NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative and impactful ideas in all markets and areas of science and engineering,” said Andrea Belz, Director of the Division of Industrial Innovation and NSF partnership. “With the support of our research funds, any tech startup or small business can guide basic science towards meaningful solutions that …
Read More On Original Publisher
This Content is Original Published by @www.businesswire.com